Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) EBITDA Margin (2017 - 2020)

Historic EBITDA Margin for Cogent Biosciences (COGT) over the last 4 years, with Q3 2020 value amounting to 16020.19%.

  • Cogent Biosciences' EBITDA Margin fell 148512700.0% to 16020.19% in Q3 2020 from the same period last year, while for Dec 2020 it was 950.43%, marking a year-over-year decrease of 8089900.0%. This contributed to the annual value of 950.43% for FY2020, which is 8089900.0% down from last year.
  • Cogent Biosciences' EBITDA Margin amounted to 16020.19% in Q3 2020, which was down 148512700.0% from 1400.19% recorded in Q2 2020.
  • Cogent Biosciences' 5-year EBITDA Margin high stood at 15.02% for Q4 2019, and its period low was 16020.19% during Q3 2020.
  • Moreover, its 4-year median value for EBITDA Margin was 325.73% (2017), whereas its average is 1478.0%.
  • Within the past 5 years, the most significant YoY rise in Cogent Biosciences' EBITDA Margin was 2959300bps (2020), while the steepest drop was -148512700bps (2020).
  • Cogent Biosciences' EBITDA Margin (Quarter) stood at 314.74% in 2017, then grew by 28bps to 225.86% in 2018, then surged by 107bps to 15.02% in 2019, then plummeted by -106725bps to 16020.19% in 2020.
  • Its EBITDA Margin stands at 16020.19% for Q3 2020, versus 1400.19% for Q2 2020 and 86.67% for Q1 2020.